secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-049866
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q3 total revenue up 69% to $87.3M; net loss $0.16/share
----------------------------------------------------------------

- U.S. net product revenue $40.7M (+31% YoY); total collaboration revenue $46.7M (+128% YoY).
- Net loss $31.3M ($0.16 diluted EPS) vs $29.5M loss ($0.15) in Q3 2024.
- Settled with Dr. Reddy's and three other ANDA filers; generic entry blocked until April 2040.
- Partner Otsuka received Japan approval and preliminary pricing for NEXLETOL, triggering milestone payments.
- Company reiterates 2025 opex guidance of $215-235M; expects sustainable profitability from Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025049866/0001628280-25-049866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828025049866/espr-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer